Device Medical Device

(2858) General Consulting

Payments companies reported to CMS as associated with (2858) General Consulting. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$86Kassociated payments (2023-2025)
20clinicians with associated payments
2companies reporting

By year

2023 $42K
2024 $44K

Payments reported as associated with (2858) General Consulting, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Clinical Cardiac Electrophysiology $34K
Critical Care Medicine (Anesthesiology) $18K
Cardiovascular Disease $8,271
Anesthesiology $6,275
Interventional Cardiology $2,208
Obstetrics & Gynecology $1,950

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with (2858) General Consulting

These are the largest totals companies reported as associated with (2858) General Consulting. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Yasmine Ali Nashville, TN $13,571.25
Romain Pirracchio San Francisco, CA Critical Care Medicine (Anesthesiology) $10,120.00
Gaurav Upadhyay Chicago, IL Clinical Cardiac Electrophysiology $6,624.00
Douglas Esberg Wynnewood, PA Clinical Cardiac Electrophysiology $6,505.95
Rakesh Latchamsetty Brighton, MI Clinical Cardiac Electrophysiology $6,395.96
Michael Balk Atlanta, GA Cardiovascular Disease $5,450.95
Joseph Schlesinger Nashville, TN Critical Care Medicine (Anesthesiology) $5,280.00
David Lin Phila, PA Clinical Cardiac Electrophysiology $5,152.00
Eric Prystowsky Indianapolis, IN Clinical Cardiac Electrophysiology $4,661.25
Amin Al-Ahmad Austin, TX Clinical Cardiac Electrophysiology $4,612.95

Prescribed (2858) General Consulting?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.